Personalized mRNA vaccines against melanoma reduced the risk of death or recurrence by 42 percent compared to standard treatment in a late-stage trial, according to an announcement by Merck and Moderna. The partners stated that the results represent a significant advance in treating the deadliest form of skin cancer and confirmed they are already engaging with regulatory authorities to seek approval for the vaccine.
Moderna CEO Stéphane Bancel said the company has long believed mRNA technology could enable cancer treatments uniquely matched to each patient's tumor. In a statement, Bancel described the trial results as a defining moment for that vision, noting that they show what is possible when rethinking how medicines are made. He added that the findings reinforce the conviction that mRNA has the potential to fundamentally change cancer treatment approaches.
The trial outcome suggests that tailored mRNA therapies could reshape future cancer care by targeting specific patient profiles.